NDRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NDRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for ENDRA Life Sciences's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
ENDRA Life Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
ENDRA Life Sciences's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:
For example, ENDRA Life Sciences's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec23 (Change) | * | Current CPI (Dec23) |
= | 0 | / | 129.4194 | * | 129.4194 | |
= | 0.000 |
Current CPI (Dec23) = 129.4194.
ENDRA Life Sciences Annual Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201412 | 17.469 | 99.070 | 22.821 |
201512 | 42.727 | 99.792 | 55.412 |
201612 | 10.118 | 101.863 | 12.855 |
201712 | 2.551 | 104.011 | 3.174 |
201812 | 0.027 | 105.998 | 0.033 |
201912 | 0.000 | 108.420 | 0.000 |
202012 | 0.000 | 109.897 | 0.000 |
202112 | 0.000 | 117.630 | 0.000 |
202212 | 0.000 | 125.222 | 0.000 |
202312 | 0.000 | 129.419 | 0.000 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
ENDRA Life Sciences (NAS:NDRA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of ENDRA Life Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Milos Thornton | officer: Chief Technology Officer | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Anthony Digiandomenico | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Alexander Y Tokman | director | C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052 |
Francois Roger Michelon | director, officer: Chief Executive Officer | 430 N. JUNO LANE, JUNO BEACH FL 33406 |
Lou Basenese | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Irina Pestrikova | officer: Senior Director, Finance | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Renaud Bertrand Maloberti | officer: Chief Commercial Officer | 10 ACORN WAY, GEORGETOWN MA 01833 |
David R. Wells | officer: Chief Financial Officer | 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405 |
Michael Harsh | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
Longboard Capital Advisors, Llc | 10 percent owner | 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212 |
Brett Conrad | 10 percent owner | 1312 CEDAR ST., SANTA MONICA CA 90405 |
Sanjiv Sam Gambhir | director | 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
From GuruFocus
By Business Wire • 08-30-2023
By Business Wire • 08-01-2023
By Business Wire Business Wire • 05-04-2023
By Business Wire Business Wire • 08-24-2022
By Business Wire Business Wire • 05-25-2022
By Business Wire Business Wire • 11-09-2022
By Business Wire Business Wire • 08-02-2022
By Business Wire • 11-08-2023
By Business Wire • 08-14-2023
By Business Wire • 11-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.